BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Quick Stats
Jan 30, 202649.4
AI Score
HOLD1.05
Volume Ratio
Next Earnings
11
+ve Days (30d)
18
-ve Days (30d)
BTAI Stock Summary
Last updated Jan 30, 2026
BTAI is currently trading at $1.59, positioned below its 200-day moving average of $2.28, suggesting bearish momentum. The stock has a 52-week range of $1.17 to $8.08.
Technical Analysis: The 50-day moving average stands at $1.87, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 34.975, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.03, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates BTAI at 49.4/100 with a HOLD recommendation.
BTAI (BioXcel Therapeutics, Inc. Common Stock) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 34.975 |
| CMF (20) | 0.03 |
| ROC (10) | -16.754 |
| ADX (14) | 16.749 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.053 |
| AROONOSC (14) | -57.143 |
| WILLAMS %R (14) | -87.5 |
| MFI (14) | 29.428 |
BTAI Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
BTAI Price vs Max Options Open Interest
BTAI Max Change In Options Open Interest
BTAI Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BTAI Daily Out of Money Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BTAI Daily In the Money Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BTAI Most Active Options by Volume(near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BioXcel Therapeutics, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
BTAI Moving Averages Analysis
BTAI (BioXcel Therapeutics, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 1.76 |
| 20 | 1.84 |
| 30 | 1.79 |
| 50 | 1.87 |
| 100 | 2.16 |
| 200 | 2.28 |
BTAI Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 36.7 million |
| Earnings/Share ($) | -9.29 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -6.7833 |
| EPS Estimate Next Year ($) | -3.105 |
| WallStreet Target Price ($) | 16.75 |
| Most Recent Quarter |
News: $BTAI stock experiences significant drop, leading to short sale restriction. Investors express frustration over economic damage and false hopes surrounding the drug. Despite criticisms, some investors remain optimistic about the biotech company's potential for long-term growth.
Updated 2025-08-28 12:00:03